Key facts
- This page summarizes Ronald K. Labrum's Form 4 filing for Ortho Clinical Diagnostics Holdings plc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2022, 16:00.
Ronald K. Labrum - 27 May 2022 Form 4 Insider Report for Ortho Clinical Diagnostics Holdings plc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 27 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jun 2022, 16:00:36 UTC
- Prior SEC filing
- 07 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael A. Schlesinger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ronald K. Labrum filed Form 4 for Ortho Clinical Diagnostics Holdings plc on 01 Jun 2022.
Change
- Previous filing in this sequence was filed on 07 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCDX
transaction
Ordinary Shares, $0.00001 par value
Disposed to Issuer
- Transaction value
- Shares
- -109,985
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 May 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Ronald K. Labrum is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Pursuant to the Business Combination Agreement, dated December 22, 2021, by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting.